Interview series with Professor Stefan Hohnloser about dual antithrombotic therapy with Dabigatran in AF patients post PCI
Should dabigatran dual therapy be the default strategy for most patients with AF and ACS?
Which dabigatran dose would be recommended for patients with AF and ACS Post-PCI?
How do the data reported on concomitant use of ticagrelor and dabigatran help inform management of patients post-ACS who underwent PCI?
Renal impairment: What can we learn from the use of dual therapy with dabigatran in patients with different renal functions?